IGC Reports Financial Results for the Quarter Ended June 30, 2022

IGC Reports Financial Results for the Quarter Ended June 30, 2022




IGC Reports Financial Results for the Quarter Ended June 30, 2022

POTOMAC, Md.–(BUSINESS WIRE)–#IGC–India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company’s 2023 fiscal year.

The highlights for the quarter are:

  • The Company has submitted a protocol to the U.S. Food and Drug Administration (FDA) titled “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease.” The protocol is powered at 146 Alzheimer’s patients with half receiving placebo and is a superiority, parallel group study. The primary end point is agitation in dementia due to Alzheimer’s disease as rated by the Cohen-Mansfield Agitation Inventory (CMAI) over a six-week period. The Company has signed agreements with trial sites for conducting the trial, pending FDA approval.
  • On June 7, 2022, the USPTO issued a patent (#11,351,152) to the Company titled “Method and Composition for Treating Seizure Disorders.” The patent relates to compositions and methods for treating multiple types of seizure disorders and epilepsy in humans and animals using a combination of the CBD with other compounds. Subject to further research and study, the combination is intended to reduce side effects caused by hydantoin anticonvulsant drugs such as phenobarbital, by reducing the dosing of anticonvulsant drugs in humans, dogs, and cats.
  • On May 10, 2022, Hamsa Biopharma India Pvt. Ltd. (“Hamsa Biopharma”), a directly owned subsidiary of the Company, completed outstanding items in the agreement executed with the Jawaharlal Nehru Centre for Advanced Scientific Research (“JNCASR”). The agreement was signed on March 28, 2022, and the Company obtained exclusive global rights to certain molecules, technology, patent, and patent filings.

Revenue was approximately $212 thousand and $77 thousand for the three months ended June 30, 2022, and June 30, 2021, respectively. Revenue in both quarters was primarily derived from our Life Sciences segment, which involved sales of products such as lotion, gummies, and alcohol-based hand sanitizers, among others.

Selling, general, and administrative (“SG&A”) expenses were approximately $1.5 million for the three months ended June 30, 2022, and approximately $1.8 million for the three months ended June 30, 2021, a decrease of approximately $226 thousand or 13% stemming mostly from a decrease in marketing and legal expenses. SG&A expenses consist primarily of employee-related expenses, sales and marketing, professional and legal fees, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any.

Research and Development (“R&D”) expenses were $1.4 million during the three months ended June 30, 2022, and approximately $444 thousand for the three-month ended June 30, 2021. The increase of approximately $950 thousand or 214% is primarily attributable to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on TGR-63. We anticipate additional increases in R&D expenses as the Phase 2 trials on IGC-AD1 commence.

Net loss for the three months ended June 30, 2022, was approximately $2.8 million or ($0.05) per share, compared to approximately $1.8 million or ($0.04) per share for the three months ended June 30, 2021.

About IGC:

IGC has two segments: Life Sciences and Infrastructure. The company is based in Maryland, U.S.A.

Forward-looking Statements: This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

< Financial Tables to Follow>

India Globalization Capital, Inc.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

(Unaudited)

 

 

 

June 30,

2022

($)

 

 

March 31,

2022

($)

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

8,053

 

 

 

 

10,460

 

Accounts receivable, net

 

 

147

 

 

 

 

125

 

Inventory

 

 

3,622

 

 

 

 

3,548

 

Deposits and advances

 

 

905

 

 

 

 

978

 

Total current assets

 

 

12,727

 

 

 

 

15,111

 

 

 

 

 

 

 

 

 

 

Intangible assets, net

 

 

937

 

 

 

 

917

 

Property, plant and equipment, net

 

 

9,161

 

 

 

 

9,419

 

Claims and advances

 

 

922

 

 

 

 

937

 

Operating lease asset

 

 

419

 

 

 

 

450

 

Total long-term assets

 

 

11,439

 

 

 

 

11,723

 

Total assets

 

 

24,166

 

 

 

 

26,834

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

456

 

 

 

 

981

 

Accrued liabilities and others

 

 

1,200

 

 

 

 

1,457

 

Short-term loans

 

 

3

 

 

 

 

3

 

Total current liabilities

 

 

1,659

 

 

 

 

2,441

 

 

 

 

 

 

 

 

 

 

Long-term loans

 

 

143

 

 

 

 

144

 

Other liabilities

 

 

16

 

 

 

 

16

 

Operating lease liability

 

 

308

 

 

 

 

341

 

Total non-current liabilities

 

 

467

 

 

 

 

501

 

Total liabilities

 

 

2,126

 

 

 

 

2,942

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies See Note 12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares

issued or outstanding as of June 30, 2022, and March 31, 2022.

 

 

 

 

 

 

 

 

Common stock and additional paid-in capital, $0.0001 par value: 150,000,000

shares authorized; 51,840,603 and 51,054,017 shares issued and outstanding

as of June 30, 2022 and March 31, 2022, respectively.

 

 

117,171

 

 

 

 

116,019

 

Accumulated other comprehensive loss

 

 

(3,187

)

 

 

 

(2,968

)

Accumulated deficit

 

 

(91,944

)

 

 

 

(89,159

)

Total stockholders’ equity

 

 

22,040

 

 

 

 

23,892

 

Total liabilities and stockholders’ equity

 

 

24,166

 

 

 

 

26,834

 

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 5, 2022.

India Globalization Capital, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except loss per share and share data)

(Unaudited)

 

 

 

Three months ended June 30,

 

 

 

2022

($)

 

 

2021

($)

 

Revenue

 

 

212

 

 

 

 

77

 

Cost of revenue

 

 

(70

)

 

 

 

(51

)

Gross profit

 

 

142

 

 

 

 

26

 

Selling, general and administrative expenses

 

 

(1,550

)

 

 

 

(1,776

)

Research and development expenses

 

 

(1,394

)

 

 

 

(444

)

Operating loss

 

 

(2,802

)

 

 

 

(2,194

)

Impairment of investment

 

 

 

 

 

 

(37

)

Other income, net

 

 

17

 

 

 

 

443

 

Loss before income taxes

 

 

(2,785

)

 

 

 

(1,788

)

Income tax expense/benefit

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

 

(2,785

)

 

 

 

(1,788

)

Foreign currency translation adjustments

 

 

(219

)

 

 

 

(86

)

Comprehensive loss

 

 

(3,004

)

 

 

 

(1,874

)

 

 

 

 

 

 

 

 

Loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic & diluted

 

$

(0.05

)

 

 

$

(0.04

)

Weighted-average number of shares used in computing loss per share

amounts:

 

 

 

51,616,598

 

 

 

 

 

47,910,866

 

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 05, 2022.

Contacts

Claudia Grimaldi

301-983-0998